Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
PBYI - Puma Biotechnology, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGS)
PumaBiotech (@pumabiotech) / X
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Articles about Puma Biotechnology
Puma Biotechnology falls more than 20%
Ex Puma Biotechnology exec Robert Gadimian charged by SEC with insider trading - L.A. Business First
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
PumaBiotech (@pumabiotech) / X
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer | Business Wire
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Upgraded by StockNews.com - MarketBeat
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Puma Biotechnology unveils Phase II breast cancer trial design
